In QuotedData’s morning briefing 1 April 2022:
- Syncona (SYNC) has provided an update on investee company Freeline, following the publication of Freeline’s full year 2021 financial results. The update highlights that:
- Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease
- Extended financial runway and streamlined organization support Company through key data readouts across all three clinical programs
- Strengthened leadership team with appointment of Chief Medical Officer and recent addition of Chief Scientific Officer
It also provides the following summary:
“2022 is shaping up to be a watershed year for Freeline, building on the strong foundation we put in place in the second half of last year,” said Michael Parini, Chief Executive Officer of Freeline. “Under new leadership, our streamlined organization has executed with urgency and increased financial discipline on a refocused set of clinical programs and corporate priorities. We also have recently strengthened our balance sheet to enable us to deliver meaningful clinical data readouts through 2022 and beyond to demonstrate the value of our promising gene therapy candidates as we advance on the path towards pivotal Phase 3 studies. Additionally, we are working on a new R&D strategy to explore the application of our science and platform technologies to new disease areas, including extending these strengths to efforts beyond rare monogenic disorders.”
- Ruffer (RICA) has published a circular to shareholders and notice of extraordinary general meeting of the Company to be held at 10.00am, on Thursday, 21 April 2022 at RICA’s registered office (Sarnia House, Le Truchot, St Peter Port, Guernsey, GY1 1GR). The purpose of the EGM is to ask shareholders for permission to issue up to another 10% of the company’s issued share capital (RICA has been in strong demand and has largely exhausted its current permissions) and to raise the cap on director’s fees from £200,000 per annum to £300,000 per annum.
- Primary Health Properties (PHP) has acquired a newly refurbished clinical facility in Chertsey, Surrey for £6.95m. The property is let on a new 20-year fully repairing and insuring (FRI) lease (meaning the tenant is responsible for all costs for repairs and insurance) to the Surrey and Borders Partnership NHS Foundation Trust and benefits from RPI led rent reviews. The site will mainly be used for drug and alcohol rehabilitation services.
We also have annual results from BlackRock Latin American and Henderson High Income, Triple Point Energy Efficiency Infrastructure’s investment in “BESS” assets, International Public Partnership’s investment in Stage 3 of the Gold Coast Light Rail Project, TRIG’s investment in a Spanish solar park, an update on the final offer for CIP Merchant Capital, and the results of Greencoat Renewables‘ placing.